相关实验视频
Updated: Sep 18, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
在帕金森病中的焦虑管理
Alex J Berry1, Harry Costello1,2, Silvia Jesús3
1Department of Neuropsychiatry, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Movement disorders clinical practice
|June 26, 2025
概括
焦虑是帕金森病 (PD) 的一个常见挑战. 本综述为检测和管理PD焦虑提供了一份指南,对抗焦虑药物的证据有限但适度.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 焦虑是帕金森病 (PD) 的普遍,具有挑战性的症状.
- 在PD中诊断和治疗焦虑通常是困难的.
- 目前的管理层缺乏正式的指导方针.
研究的目的:
- 为识别和管理帕金森病中的焦虑提供实用指南.
- 审查当前的药物和非药物治疗选择.
- 介绍PD中焦虑治疗的元分析.
主要方法:
- 教育审查焦虑现象学,诊断,神经生物学和PD的治疗理由.
- 对主要药物类别和非药理学方法的审查.
- 在PD中使用抑郁症RCT的二次结果对焦虑的药理疗法的分析.
主要成果:
- 与安慰剂相比,抗焦虑药物表现出适度的影响 (SMD: -0.45,p=0.02).
- 包括的研究存在局限性,包括小样本大小和特定药物疗法的有限复制.
- 为个性化药物管理开发了一个务实的算法.
结论:
- 检测和治疗焦虑可能有利于帕金森病患者.
- 对于PD中的特定焦虑治疗的证据基础仍然有限.
- 需要进一步的研究,以建立基于证据的管理策略.
相关概念视频
01:24Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
01:15Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
01:26Anxiolytic Drugs: Overview
511
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
511
01:18Anxiety: Overview
374
Anxiety is a common mental disorder featuring excessive worry, fear, and apprehension, significantly affecting daily life. People with anxiety disorders experience persistent and intense anxiety, interrupting their everyday functioning.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
374
01:30Generalized Anxiety Disorder
214
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
214
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265